Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Winer

Showing results (51-60 of 105) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840Andrew D Seidman, Donald Berry, Constance Cirrincione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Correction: <sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent TrialsYingbing Wang, Karen L Ayres, Debra A Goldman, et al.
JAMA Oncology|October 6, 2022
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and MisinterpretationsFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Breast Cancer Research and Treatment|October 6, 2016
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)Mehra Golshan, Constance T Cirrincione, William M Sikov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2016
<sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent TrialsYingbing Wang, Karen L Ayres, Debra A Goldman, et al.
Breast Cancer Research and Treatment|June 15, 2006
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806Mercedes Rincon, Gloria Broadwater, Lyndsay Harris, et al.
Journal of Cancer Survivorship : Research and Practice|June 12, 2014
Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901Leigh Anne Faul, Gheorghe Luta, Vanessa Sheppard, et al.
Journal of Cellular and Molecular Medicine|January 17, 2020
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutationsEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancerFrancisco J Esteva, John Glaspy, Said Baidas, et al.
Archives of Pathology & Laboratory Medicine|January 7, 2009
Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breastSusan C Lester, Shikha Bose, Yunn-Yi Chen, et al.
Pageof 11

Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840Andrew D Seidman, Donald Berry, Constance Cirrincione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Correction: <sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent TrialsYingbing Wang, Karen L Ayres, Debra A Goldman, et al.
JAMA Oncology|October 6, 2022
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and MisinterpretationsFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Breast Cancer Research and Treatment|October 6, 2016
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)Mehra Golshan, Constance T Cirrincione, William M Sikov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2016
<sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent TrialsYingbing Wang, Karen L Ayres, Debra A Goldman, et al.
Breast Cancer Research and Treatment|June 15, 2006
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806Mercedes Rincon, Gloria Broadwater, Lyndsay Harris, et al.
Journal of Cancer Survivorship : Research and Practice|June 12, 2014
Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901Leigh Anne Faul, Gheorghe Luta, Vanessa Sheppard, et al.
Journal of Cellular and Molecular Medicine|January 17, 2020
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutationsEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancerFrancisco J Esteva, John Glaspy, Said Baidas, et al.
Archives of Pathology & Laboratory Medicine|January 7, 2009
Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breastSusan C Lester, Shikha Bose, Yunn-Yi Chen, et al.
Pageof 11